Anti-Mouse CD366 (Tim-3) [RMT3-23] – Purified in vivo GOLD™ Functional Grade

This antibody was produced using recombinant mouse TIM-3

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

B
IHC

Tim-3 antibody (clone RMT2-23) recognizes an epitope on mouse Tim-3.

Tim-3 antibody (clone RMT3-23) recognizes T cell immunoglobulin and mucin domain-containing protein 3 (TIM3, also known as CD366), a TIM family member of immunoregulatory proteins. Tim-3 is a 60kDa type I transmembrane protein with an extracellular immunoglobulin and mucin-like domain and a cytoplasmic tyrosine phosphorylation motif. Tim-3 is expressed by IFNg-producing Th1 CD4 and Tc1 (cytotoxic) CD8 T cells¹, regulatory T cells (Tregs)², myeloid cells³, NK cells⁴, and mast cells⁵. Tim-3 is an inhibitory molecule that limits Th1-mediated inflammatory diseases, including a model of central nervous system inflammation (experimental autoimmune encephalomyelitis, EAE)¹, inflammatory bowel disease (IBD)⁶, and type I diabetes⁷. Tim-3 is also proposed to induce immunological tolerance⁷, promote Th1 apoptosis⁸, and regulate macrophage activation1. In addition, Tim-3 is upregulated on tumor-infiltrating lymphocytes, and coblockade of Tim-3 and immune checkpoint inhibitors, such as PD-1, is currently being investigated in clinical trials for the treatment of cancer⁹.

Tim-3 is expressed on activated Th1 and Tc1 lymphocytes, CD11b+ macrophages, Tregs, NK cells, and mast cells.

Putative ligand on resting CD4+ lymphocytes

May play a role in the development of immune responses and the development of Th1-mediated responses

1. Monney, L. et al. (2002)Nature 415, 536–541.
2. Gao, X. et al. (2012) PLOS ONE 7, e30676.
3. Anderson, A. C. et al. (2007) Science 318, 1141–1143.
4. Ndhlovu, L. C. et al. (2012) Blood 119, 3734–3743.
5. Phong, B. L. et al. J. (2015) Exp. Med. 212, 2289–2304.
6. Li, X. et al. (2010) Clin. Immunol. 134, 169–177.
7. Sanchez-Fueyo, A. et al. (2003) Nat. Immunol. 4, 1093–1101.
8. Zhu C, et al.. Nature Immunology. 2005;6:1245–1252.